In this prospective study, we assessed the incidence of central venous catheter (CVC)-related thrombosis in haematopoietic stem cell transplant (HSCT) recipients. We determined the contribution of inherited prothrombotic abnormalities in blood coagulation to CVC-related thrombosis in these patients. The study was conducted between May 2002 and September 2004. CVCs were externalized, nontunneled, polyurethane double lumen catheters. Before catheter insertion, laboratory prothrombotic markers included factor V Leiden, the prothrombin gene Gly20210A mutation, plasma antithrombin levels, and protein C and S activity. All patients were systematically examined by ultrasonography just before, or o24 h after, catheter removal, and in case of clinical signs of thrombosis. A total of 171 patients were included during the 28-month study period. Five (2.9%) and three (1.7%) patients had evidence of protein C and protein S deficiency, respectively. Only one patient had an antithrombin deficiency (0.6%). In total, 10 patients (5.8%) were heterozygous for the factor V Leiden mutation, and one patient had heterezygous prothrombin G20210A mutation (0.6%). We observed a CVC-related thrombosis in 13 patients (7.6%). Thrombosis was diagnosed in four out of 20 patients (20%) with a inherited prothrombotic abnormality compared to nine of 151 patients (6%) who did not have a thrombophilic marker (relative risk 3.3 CI 95% 1.1-9.9). Our results suggest that inherited prothrombotic abnormalities contribute substantially to CVC-related thrombosis in HSCT recipients. In view of physicians' reluctance to prescribe prophylactic anticoagulant treatment in these patients, a priori determination of inherited prothrombotic abnormalities may form a basis to guide these treatment decisions. Patients undergoing haematopoietic stem cell transplantation (HSCT) require central venous catheters (CVC) for the administration of medication, blood products, parenteral nutrition and for blood sampling.
1-2 The benefit derived from these devices can be offset by thrombosis, which may be complicated by pulmonary embolism and CVC dysfunction. [3] [4] [5] Routine venography of asymptomatic patients undergoing autologous or allogeneic bone marrow transplantation reveals a thrombosis rate that varies from 4 to 42%. [6] [7] [8] [9] [10] A large number of studies have been published addressing the association of inherited prothrombotic abnormalities with deep vein thrombosis of the leg and pulmonary embolism.
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In contrast, studies in HSCT recipients investigating the association of these risk factors with CVC-related thrombosis are scarce. 12 In a prospective setting, we assessed the incidence of CVC-related thrombosis in HSCT recipients undergoing catheterization via the subclavian vein. We determined the contribution of inherited prothrombotic abnormalities (factor V Leiden, prothrombin G20210A mutation, plasma antithrombin levels, and protein C and S activity) to CVCrelated thrombosis in these patients. In addition, all patients were assessed for other potential risk factors for CVC-related thrombosis.
Patients and methods

Study design
This prospective study was conducted between May 2002 and September 2004 at the 'National Centre for Bone Marrow Transplantation', Tunisia. The study protocol was approved by the local medical ethical committee, and written informed consent was obtained from the patients or their legal representatives.
Patient population
Patients were eligible for the study if they had an HSCT and a nontunnelled CVC. Exclusion criteria were the presence of a CVC on admission, a contraindication to the use of subclavian catheterization due to major blood coagulation disorders (ie platelet count o50 Â 10 9 /l, disseminated intravascular coagulation), a history of a CVC at the same insertion site, or a history of an objectively confirmed thrombosis at the same insertion site. Some patients received prophylactic intravenous unfractionated heparin (UFH) (continuous infusion of 100 IU/kg/daily).
Inherited prothrombotic markers
Before catheter insertion, laboratory prothrombotic markers included the factor V Leiden, the prothrombin gene Gly20210A mutation, plasma antithrombin levels, and protein C and S activity. [13] [14] [15] The investigator was blinded for the presence of thrombotic complications. The physician was not aware of the prothrombotic marker status.
Central venous catheter characteristics
CVCs were externalized, nontunnelled, polyurethane double lumen catheters (Arrows, Readings, USA). Catheter sizes were chosen appropriate to age (5 or 7 French diameter). The physician wore mask, cap, sterile gloves, and surgical gowns and used large sterile drapes. The skin insertion site was disinfected with povidone iodine. All CVCs were placed in the subclavian vein by the infraclavicular approach, by the same physician, in the operating room. Catheters were inserted percutaneously, using the Seldinger technique. 16 The CVC tip was confirmed radiographically to lie in the superior vena cava. Study catheters were not exchanged over guidewires. The insertion sites were covered with a transparent sterile dressing (Tegaderm, Healthcare, USA). Catheter care included changing of the dressing under aseptic conditions every 6 days. Insertion sites were examined daily for the presence of signs of catheter-related thrombosis (eg arm or neck pain, localized erythema, arm swelling, or dilated superficial collateral veins). Results of the daily examinations were recorded.
Outcome assessment
The primary end point in this study was CVC-related thrombosis. Two types of thromboses were distinguished: clinically manifest thrombosis and subclinical thrombosis. Clinically manifest thrombosis was defined as thrombosis objectively identified by Doppler-ultrasound following signs or symptoms suggestive of CVC-related thrombosis, as noted by the attending physicians. Subclinical thrombosis was defined as thrombosis demonstrated by Dopplerultrasound in the absence of signs or symptoms.
In our study, all patients were systematically examined by ultrasonography just before, or o24 h after, catheter removal, and in case of clinical signs of thrombosis. Two radiologists performed the ultrasonography. In the event of disagreement between these two, a third expert opinion was sought. The ultrasound examination was performed bilaterally. The following venous segments were identified subsequently: brachial, axillary, subclavian, and jugular vein. For veins accessible to direct insonation, criteria considered to show the presence of catheter-related thrombosis included visualization of thrombosis, absence of spontaneous flow, dilatation of the vein by the Valsalva maneuvre and noncompressibility of the vein. [17] [18] For veins inaccessible to direct insonation (middle part of the subclavian vein, brachiocephalic vein, and superior caval vein), the criterion of monophasic flow to detect occlusive thrombosis was used. 19 All CVCs were removed before discharge. Clinical follow-up took place for 8 weeks after CVC removal.
In patients with a documented thrombus, the catheter was removed and UFH (prolonging the APTT by two-to 2.5-fold) was given intravenously, followed by oral vitamin K antagonist (INR: 2-3).
Data collection
Standardized data collection forms were completed for all patients. These data included demographic characteristics, underlying disease, type of transplantation, catheter insertion and removal date, body side of CVL location (right, left), duration of insertion (in minutes), and number of attempts at placement.
Statistics
Cumulative incidences for subclinical thrombosis and clinically manifest thrombosis were calculated as the number of first events over the number of patients at baseline. The ratios of the cumulative incidences were the relative risks (RR). 95% confidence intervals (CI 95%) were based on standard errors for binomial distributions. The effects of risk factors that were likely to be associated were determined by restriction analysis.
Results
A total of 171 patients were included during the 28-month study period. The main characteristics of these 171 patients and their CVC are shown in Table 1 .
CVC-related thrombosis
Overall, 7.6% (13 out of 171) of patients developed CVCrelated thrombosis. The median time to thrombosis from insertion of the CVC was 23 days (8-41). In eight patients (4.6%) the thrombosis was clinically manifest, while in five patients (3%) a subclinical thrombosis was found. No patients developed pulmonary embolism.
Risk estimates for CVC-related thrombosis
Five (2.9%) and three (1.7%) patients had evidence of protein C and protein S deficiency, respectively. Only one patient had an antithrombin deficiency (0.6%). In total, 10 patients (5.8%) were heterozygous for the factor V Leiden Prevalence of inherited prothrombotic abnormalities and CVC-related thrombosis A Abdelkefi et al mutation and one patient had the heterozygous prothrombin G20210A mutation (0.6%). No patient was double heterozygous or homozygous. Thrombosis was diagnosed in three out of 10 patients (30%) with factor V Leiden as compared to 10 of 161 (6.2%) who did not have the mutation (RR 4.8, CI 95% 1.5-14.8). The median time to thrombosis in patients with factor V Leiden was 22 days (8-40) compared to 24 days (8-41) in the patients without the mutation (NS). Thrombosis was diagnosed in one out of five (20%) patients with protein C deficiency, whereas 12 thromboses were detected in 166 patients (7.2%) without protein C deficiency. We did not observe thrombosis in patients with protein S deficiency, prothrombin G20210A mutation, or antithrombin deficiency. For patients with CVC-related thrombosis who had at least one of the inherited prothrombotic markers, the relative risk was 3.3 (CI 95% 1.1-9.9) ( Table 2) .
The risk estimates of other factors for CVC-related thrombosis are summarized in Table 3 . On univariate analysis, an absence of UFH prophylaxis was associated with an increased risk of CVC-related thrombosis. No other substantial contributors to CVC-related thrombosis could be identified.
With regard to clinically manifest thrombosis, a similar trend was observed for the inherited coagulation disorders, and the absence of UFH prophylaxis. Three out of 20 patients (15%) with an inherited coagulation disorder (in all cases heterozygous factor V Leiden) developed clinically manifest thrombosis, compared to five out of 151 (3.3%) patients without the mutation (RR 4.5, CI 95% 1.1-17.5). Prevalence of inherited prothrombotic abnormalities and CVC-related thrombosis A Abdelkefi et al
The absence of UFH prophylaxis was strongly associated with an increased risk of clinically manifest thrombosis. Six out of 81 (7.4%) patients without UFH prophylaxis developed clinically manifest thrombosis, compared to two out of 90 (2.2%) patients with UFH prophylaxis (RR 3.3, CI 95% 0.6-16.0).
Discussion
CVC-related thrombosis is a serious complication in HSCT recipients. There is a high morbidity associated with venous thrombosis and, in addition, a small risk of pulmonary embolism. The catheter needs to be removed during a critical phase when the patient is still aplastic, needs parenteral nutrition, blood products, and frequent blood sampling.
Reliable data concerning the association between inherited coagulation disorders and CVC-related thrombosis in cancer patients are scarce and contradictory. In our study, all catheters were inserted percutaneously by the same physician, in the subclavian vein. All CVCs were externalised, nontunnelled polyurethane catheters. In the present study of 171 HSCT recipients, we found a clear relationship between factor V Leiden and CVC-related thrombosis. Indeed, factor V Leiden carriers had a 4.8-fold increased risk of subclavian vein thrombosis after an HSCT. In addition, an absence of UFH prophylaxis was associated with CVC-related thrombosis.
In a study of patients undergoing bone marrow transplantation, a 54% frequency of clinically manifest thrombosis (seven of 13 patients) in patients who were heterozygous for factor V Leiden was reported, whereas in patients without factor V mutation a 10% risk was found (26 of 264 patients). The reported relative risk (Cox proportional hazard model) from this study was 7.7 (CI 95%; 3.3-17.9). 12 In a smaller study in which 82 cancer patients with a CVC were evaluated, prothrombotic risk factors, including factor V Leiden, were not substantial predictors of clinically manifest thrombosis, although the data suggested that factor V Leiden increased the risk of thrombosis. 20 However, the statistical power of this study was limited because of the small numbers of patients with thrombosis and factor V Leiden. 20 In one other study it was reported that factor V Leiden did not contribute to CVC-related thrombosis. 21 In this case-control study, the prevalence of factor V Leiden in patients with thrombosis (7.4%, two of 27 patients) was not observed to be higher than the prevalence in the general Western population (5%).
The contribution of protein C and S deficiency, prothrombin G20210A mutation, and antithrombin deficiency to CVC-related thrombosis was not assessed in these studies. 12, [20] [21] In a recent prospective study, van Rooden et al 22 have shown in 252 patients (54% with malignant disease) a cumulative incidence of CVC-related thrombosis of 30% (clinically manifest thrombosis: 7%). The relative risk of factor V Leiden or prothrombin G20210A mutation for thrombosis was 2.7 (CI 95% 1.9-3.8). In addition, a personal history of venous thrombosis was associated with CVC-related thrombosis, whereas the severity of thrombosis was influenced by the presence of cancer and the absence of anticoagulants.
Indeed, data from two randomised controlled trials in cancer patients with a CVC have supported the use of routine anticoagulant prophylaxis. [23] [24] Recently, in a randomised controlled trial, we showed that low-dose of UFH was safe and effective to prevent CVC-related thrombosis in patients with haemato-oncological disease. 25 However, many clinicians are reluctant to prescribe anticoagulant prophylaxis routinely in patients with cancer and a CVC because of the low expected incidence of thrombosis and the fear of bleeding during anticoagulant prophylaxis. [26] [27] In conclusion, our results suggest that inherited prothrombotic abnormalities contribute substantially to CVC-related thrombosis in HSCT recipients. In view of physicians' reluctance to prescribe prophylactic anticoagulant treatment in these patients, a priori determination of inherited prothrombotic abnormalities may form a basis to guide these treatment decisions.
